Higher radiation doses for treating recurrent ventricular tachycardia
Official title: Dose Escalation for Stereotactic Cardiac Radiation Therapy of Recurrent Ventricular Tachyarrhythmia - a Multi Center, Phase II Clinical Trial
Run by University of Zurich · NCT05594368 · Data updated 2026-11-12
This study is testing if higher doses of targeted radiation can help people with recurrent ventricular tachycardia who haven't had success with other treatments.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | University of Zurich Academic / other |
| Drugs / interventions | radiation |
| Locations | 3 sites (Ostrava and 2 other locations) |
| Status | Recruiting |
| Started | July 1, 2022 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | August 21, 2026 |
| Trial ID | NCT05594368 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with structural heart disease and a history of recurrent VT despite previous ablation attempts.
✕Probably not a fit
Patients with only premature ventricular contractions or those with reversible causes of VT may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of dose-escalated stereotactic arrhythmia radioablation in patients with recurrent ventricular tachycardia (VT). The study hypothesizes that higher radiation doses will promote transmural scar formation, which is believed to be crucial for reducing long-term VT recurrence rates. Participants will include those with structural heart disease who have previously failed catheter ablation attempts. The trial will assess the safety and efficacy of this approach compared to the standard single dose of 25 Gy.
Why it matters
Potential benefit: If successful, this approach could significantly lower the recurrence rate of ventricular tachycardia in patients who have not responded to traditional treatments.
How similar studies have gone: While this approach is innovative, similar studies have not been widely reported, indicating a novel exploration in the treatment of recurrent VT.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with structural heart disease, in particular ischemic and non-ischemic cardiomyopathy: Implanted ICD and/or CRT-D. Prior ≥1 failed catheter ablation (with endocardial ± epicardial approach based on the substrate location and the ECG morphology of clinical VTs) procedure to control sustained monomorphic VT using currently recommended mapping and ablation techniques,2 or patients in whom ablation is not feasible. Reasons for lack of epicardial ablation and non-feasibility of catheter ablation must be specified. Sustained VT recurrence after catheter ablation on optimised antiarrhythmic medication. Age ≥18 years. IRB-approved, written informed consent must be provided Exclusion Criteria: Patients with only premature ventricular contractions. Patients with sustained VT/VF who demonstrate: Acute myocardial infarction; Primary electrical disease (channelopathy); Reversible and treatable cause (e.g., drug-induced or intoxication) of VT that can be adequately addressed otherwise; A target that cannot be safely and precisely defined based on stereotactic radiotherapy accuracy requirements (e.g., anatomical interference from OARs, overlapping prior radiation therapy to the thoracic region); Pregnancy or breastfeeding; Inability to provide informed consent.
Where it's running
-
University Hospital Ostrava
Ostrava, Czechia Recruiting -
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland Recruiting -
Inselspital Bern
Bern, Switzerland Recruiting
Study contacts
- Study coordinator: Nicolaus Andratschke, MD
- Email: nicolaus.andratschke@usz.ch
- Phone: 0041 44 255 4238
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-powered ECG to help diagnose and locate tachycardia in patients with PSVT, WPW, PVC, or VT
A multicenter registry test whether an AI-enabled ECG analysis can help diagnose and localize tachycardia in adults with certain arrhythmias.
-
DuoVT PFA System for Treating Ventricular Tachycardia
This study tests whether the DuoVT Pulsed Field Ablation system can safely and effectively treat Ventricular Tachycardia in people with ischemic heart disease.
-
Sphere VT: Using Sphere-9 Catheter and Affera System to treat recurrent scar-related ventricular tachycardia
This study tests the Sphere-9 catheter and Affera mapping and ablation system in adults with recurring scar-related ventricular tachycardia after a prior heart attack.
-
Parasternal EV-ICD System Pivotal Study
This study tests the Parasternal Extravascular ICD System in adults who need an ICD to see if it can safely provide defibrillation without traditional leads.
-
Real-time intracardiac ultrasound to guide ablation of ventricular arrhythmias
It tests whether using ultrasound inside the heart during PVC or VT ablation can reduce X-ray exposure for adults having these procedures.
-
Arrhythmia mapping with a paddle-shaped multi-electrode catheter
This test uses a new high-density multi-electrode catheter to see if it can safely map atrial and ventricular arrhythmias in adults having catheter mapping and ablation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.